Kezar Life Sciences acquired by Aurinia for $6.955/sh + CVR; stock to be delisted

Kezar Life Sciences, Inc.

Tender offer expired May 8, 2026; 5,927,580 shares (80.2% of outstanding) validly tendered.
Merger completed May 11, 2026 under DGCL Section 251(h); Kezar became wholly owned subsidiary of Aurinia.
Consideration: $6.955 per share in cash plus one contingent value right per share (CVR Agreement filed as Exhibit 10.1).
Entire board (7 directors) resigned; Kevin Tang and others from Merger Sub became directors and officers of surviving corporation.
Shares will be suspended and delisted from Nasdaq; company intends to file Form 15 to terminate registration.

item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 9.01

Source: SEC EDGAR

accession 0001140361-26-020407

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.